Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

Vertex Pharmaceuticals (VRTX) reported $2.77 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 11.6%. EPS of $4.38 for the same period compares to ...

The choice to switch to a Qualcomm SoC should have come with some advantage over other systems, but our testing couldn’t really find one. The Dell Inspiron 14 (5441) is yet another iteration of ...

We're starting to hit the Black Friday deals season now and Dell is just one of the many retailers to have launched superb early deals this week. Dubbed the 'Early Holiday Savings sale ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed yesterday at $472.80.

Average portfolio weight of all funds dedicated to VRTX is 0.51%, an increase of 5.07%. Total shares owned by institutions increased in the last three months by 1.10% to 287,243K shares.

While there are several candidates to make the next stock split announcement, Vertex Pharmaceuticals (NASDAQ:VRTX) may just trump them all when it reports earnings on Nov. 4. Just because a stock ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $540.00. The company’s shares closed ...